Treatment of Drug Resistant TB - Questions

Slides:

Advertisements

Similar presentations

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Advertisements

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

TREATMENT OF TUBERCULOSIS, 2003

Latent Infection of Tuberculosis in China HUASHAN HOSPITAL, FUDAN UNIVERSITY, Shanghai, China Wenhong Zhang, M.D & PhD.

Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November.

Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.

Adverse Drug Reactions to Anti-TB drugs Dr M A Jalil Chowdhury Professor of Medicine Bangabandhu Sheikh Mujib Medical University.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

7. Anti-TB regimen in special situations of liver disease, renal impairment, and pregnancy.

XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,

Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.

Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.

HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,

MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant

1 Introduction to Drug-Resistant TB Session 2. USAID TB CARE II PROJECT Classification of drug-resistant TB “Drug-resistant TB” is a general term to describe.

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,

Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.

Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

Development and evaluation of software to support prescribing and drug supply management in the treatment of MDR-TB in Peru. Fraser H, Choi S, Jazayeri.

By Luke Carroll 1B.   Tuberculosis (TB) is an infectious disease that usually infects the lungs, but can attack almost any part of the body. What Is.

Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.

Trials and evidence in relation to health policy: The case of tuberculosis in Nepal and India Ian Harper.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

Molecular diagnosis of drug resistant tuberculosis by a DNA array

Will Personalized Medicine be the clue to eradicate TB?. Pere-Joan Cardona CONFER È NCIA DE L ’ EUROPAN PARLIAMENTARY TECHNOLOGY.

Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.

By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

Anti-tuberculosis drugs. First-line drugs Isoniazid (INH or H) Rifampin (RMP or R) Ethambutol (EMB or E) Pyrazinamide (PZA or Z)

MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.

Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.

Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.

Drug Resistant Tuberculosis

Treatment for Multi-drug Resistant TB

STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL

Dose and range (mg/kg body weight)

MULTI DRUG RESISTANCE (MDR) TUBERCULOSIS :

Antimycobacterial Drugs

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates Muthuraj Muthaiah,

Treatment of TB Disease

CHM 708 Anti-Bacterial Drugs.

1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB

Dr Dawood Quiz questions.

Drug Resistant (DR) TB (Back to Basics)

Drug resistant tuberculosis

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

Richard Laing, Kelly McGoldrick

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary.

Antimycobacterial Drugs

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Clinical Epidemiology and Global Health

Pharmacology 3 Antimycobacterial drugs Lecture 12 By Prof. Dr

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

CASE HOLDING FOR PMDT.

Presented by: Dr. Letshufi DSV 04th August 2016 Pretoria

Lecture 5 By Prof. dr. Mohammed Fahmy

Diversity of resistant and susceptible isolates.

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Presentation transcript:

Treatment of Drug Resistant TB - Questions Nesri Padayatchi

Isoniazid mono- resistance is usually treated with Rifampicin, Isoniazid, pyrazinamide and Ethambutol in the intensive phase and then only Rif and INH in the continuation phase Rifampicin, Isoniazid, Pyrazinamide and Ethambutol for 6-9 months Rifampicin, Moxifloxacin, Kanamycin for Rifampicin, INH and Kanamycin Rifampicin, INH, Moxifloxacin and Kanamycin Correct answer is 2

MDRTB is TB that is resistant to… Rifampicin At least Rifampicin and INH Rifampicin, INH and Moxifloxacin Rifampicin, INH and Kanamycin Rifampicin, INH, Moxifloxacin and Kanamycin Correct answer is 2

Standard MDR-TB treatment is usually Streptomycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, Kanamycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, Capreomycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, 2 is correct

An inhA mutation confers resistance to which drug? Moxifloxacin Rifampicin High Dose INH Ethionamide Terizidone 4 is correct

A katG mutation confers resistance to which drug? Moxifloxacin Rifampicin High Dose INH Ethionamide Terizidone 3 is correct